Familial Mediterranean Fever in Crete: A genetic and structural biological approach in a population of 'intermediate risk'

Clinical Genetics

Volumn 73, Issue 2, 2008, Pages 152-159

  Fragouli, E ^a   Eliopoulos, E ^b   Petraki, E ^a   Sidiropoulos, P ^c   Aksentijevich, I ^d   Galanakis, E ^c   Kritikos, H ^c   Repa, A ^c   Fragiadakis, G ^e   Boumpas, D T ^a,c   Goulielmos, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^e Depatrment of Gastroenterology   (Greece)

Author keywords

Dimensional model (3D model); Familial mediterranean fever (FMF); MEFV; Mutational analysis; Phylogenetic tree; Pyrin; Three

Indexed keywords

CYTOSKELETON PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MARENOSTRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHEMICAL STRUCTURE; CHILD; COHORT ANALYSIS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE FREQUENCY; GENETICS; GREECE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; PHYLOGENY;

ADOLESCENT; ADULT; CASPASE 1; CHILD; COHORT STUDIES; CYTOSKELETAL PROTEINS; FAMILIAL MEDITERRANEAN FEVER; FEMALE; GENE FREQUENCY; GREECE; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PHYLOGENY;

EID: 38349115445     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2007.00948.x     Document Type: Article

References (54)

1. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967: 43: 227-253.
2. Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 2006: 18: 108-117.
3. Grateau G, Pecheux C, Cazeneuve C et al. Clinical versus genetic diagnosis of familial Mediterranean fever. QJM 2000: 93: 223-229.
4. Hull KM, Shoham N, Chae J, Aksentijevich I, Kastner DL. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003: 15: 61-69.
5. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997: 17: 25-31.
6. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997: 90: 797-807.
7. Schaner P, Richards N, Wadhwa A et al. Episodic evolution of pyrin in primates: human mutations recapitulate ancestral amino acid states. Nat Genet 2001: 27: 318-321.
8. Schaner PE, Gumucio DL. Familial Mediterranean fever in the post-genomic era: how an ancient disease is providing new insights into inflammatory pathways. Curr Drug Targets Inflamm Allergy 2005: 4: 67-76.
9. Bertin J, DiStefano PS. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ 2000: 7: 1273-1274.
10. Martinon F, Hofmann K, Tschopp J. The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation. Curr Biol 2001: 11: R118-R120.
11. Chae JJ, Wood G, Masters SL et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006: 103: 9982-9987.
12. Grutter C, Briand C, Capitani G et al. Structure of the PRYSPRY-domain: implications for autoinflammatory diseases. FEBS Lett 2006: 580: 99-106.
13. Goulielmos GN, Fragouli E, Aksentijevich I, Sidiropoulos P, Boumpas DT, Eliopoulos E. Mutational analysis of the PRYSPRY domain of pyrin and implications for familial Mediterranean Fever (FMF). Biochem Biophys Res Commun 2006: 345: 1326-1332.
14. Aksentijevich I, Torosyan Y, Samuels J et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 1999: 64: 949-962.
15. Gershoni-Baruch R, Brik R, Shinawi M, Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002: 10: 145-159.
16. Majeed H, El-Khateeb M, El-Shanti H, Rabaiha ZA, Tayeh M, Najib D. The spectrum of familial Mediterranean fever gene mutations in Arabs: report of a large series. Semin Arthritis Rheum 2005: 34: 813-818.
17. Konstantopoulos K, Kanta A, Deltas K et al. Familial Mediterranean fever associated pyrin mutations in Greece. Ann Rheum Dis 2003: 62: 479-481.
18. Konstantopoulos K, Kanta A. Familial Mediterranean fever seems to be not uncommon in Greece. Eur J Hum Genet 2004: 12: 85-86.
19. Giaglis S, Papadopoulos V, Kambas K et al. MEFV alterations and population genetics analysis in a large cohort of Greek patients with familial Mediterranean fever. Clin Genet 2007: 71: 458-467.
20. Deltas K, Mean R, Rossou E et al. Familial Mediterranean fever (FMF) mutations occur frequently in the Greek- Cypriot population of Cyprus. Genet Test 2002: 6: 15-21.
21. Rossou E, Kouvatsi A, Aslanidis C, Deltas C. Multiplex molecular diagnosis of MEFV mutations in patients with familial Mediterranean fever by LightCycler real-time PCR. Clin Chem 2005: 51: 1725-1727.
22. La Regina M, Nucera G, Diaco M et al. Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet 2003: 11: 50-56.
23. Aldea A, Calafell F, Arostegui JI et al. The west side story: MEFV haplotype in Spanish FMF patients and controls, and evidence of high LD and a recombination 'hotspot' at the MEFV locus. Hum Mutat 2004: 23: 399-406.
24. Suzuki T, Nakamura A, Yazaki M, Ikeda S. A Japanese case of familial Mediterranean fever with homozygosity for the pyrin E148Q mutation. Intern Med 2005: 44: 765-766.
25. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 2001: 9: 473-483.
26. Ritis K, Giaglis S, Spathari A et al. Non-isotopic RNase cleavage assay for mutation detection in MEFV, the gene responsible for familial Mediterranean fever, in a cohort of Greek patients. Ann Rheum Dis 2004: 63: 438-443.
27. Peltonen L, Palotie A, Lange K. Use of population isolates for mapping complex traits. Nat Rev Genet 2000: 1: 182-190.
28. Patrinos GP, Kollia P, Loutradi-Anagnostou A, Louko-poulos D, Papadakis MN. The Cretan type of non-deletional hereditary persistence of fetal hemoglobin [A gamma-158C/T] results from two independent gene conversion events. Hum Genet 1998: 102: 629-634.
29. Arnaiz-Villena A, Iliakis P, Gonzalez-Hevilla M et al. The origin of Cretan populations as determined by characterization of HLA alleles. Tissue Antigens 1999: 53: 213-226.
30. Apostolakis S, Baritaki S, Krambovitis E, Spandidos DA. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population. J Clin Virol 2005: 34: 310-314.
31. Stiakaki E, Germanakis I, Sfyridaki C, Katzilakis N, Danilatou V, Kalmanti M. Prevalence of Factor V Leiden and other thrombophilic traits among Cretan children with malignancy. Pediatr Blood Cancer 2005: 444: 386-389.
32. Plaitakis A, Viskadouraki AK, Tzagournissakis M et al. Increased incidence of sporadic Creutzfeldt-Jakob disease on the island of Crete associated with a high rate of PRNP 129-methionine homozygosity in the local population. Ann Neurol 2001: 50: 227-233.
33. Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997: 40: 1879-1885.
34. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993: 234: 779-815.
35. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci U S A 2007: 104: 6200-6205.
36. Chen R, Li L, Weng Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins 2003: 52: 80-87.
37. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy minimization and dynamics calculations. J Comput Chem 1983: 4: 165-175.
38. QUANTA: a molecular graphics program licensed to molecular simulations. San Diego, CA: Accelrys Software Inc., 1998.
39. Mor A, Shinar Y, Zaks N et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum 2005: 35: 57-64.
40. El-Shanti H, Majeed HA, El-Khateeb M. Familial Mediterranean fever in Arabs. Lancet 2006: 367: 1016-1024.
41. Kogan A, Shinar Y, Lidar M et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001: 102: 272-276.
42. Stoffman N, Magal N, Shohat T et al. Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 2000: 8: 307-310.
43. Sarkisian T, Ajrapetyan H, Shahsuvaryan G. Molecular study of FMF patients in Armenia. Curr Drug Targets Inflamm Allergy 2005: 4: 113-116.
44. Medlej-Hashim M, Serre JL, Corbani S et al. Familial Mediterranean fever (FMF) in Lebanon and Jordan: a population genetics study and report of three novel mutations. Eur J Med Genet 2005: 48: 412-420.
45. Lachmann HJ, Sengul B, Yavuzsen TU et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006: 45: 746-750.
46. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford) 2004: 43: 410-415.
47. Ozen S, Balci B, Ozkara S et al. Is there a heterozygote advantage for familial Mediterranean fever carriers against tuberculosis infections: speculations remain? Clin Exp Rheumatol 2002: 20: S57-S58.
48. Dolberg OT, Alkan M, Schlaeffer F. Tuberculosis in Israel: a 10-year survey of an immigrant society. Isr J Med Sci 1991: 27: 386-389.
49. Cattan D. Familial Mediterranean fever: is low mortality from tuberculosis a specific advantage for MEFV mutations carriers? Mortality from tuberculosis among Muslims, Jewish, French, Italian and Maltese patients in Tunis (Tunisia) in the first half of the 20th century. Clin Exp Rheumatol 2003: 21: S53-S4.
50. Cattan D. MEFV mutation carriers and diseases other than familial Mediterranean fever: proved and non-proved associations; putative biological advantage. Curr Drug Targets Inflamm Allergy 2005: 4: 105-112.
51. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986: 314: 1001-1005.
52. Shinar Y, Livneh A, Langevitz P et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol 2000: 27: 1703-1707.
53. Spanaki C, Plaitakis A. Bilineal transmission of Parkinson disease on Crete suggests a complex inheritance. Neurology 2004: 62: 815-817.
54. DeLano WL. 'The PyMOL molecular graphics system'. San Carlos, CA: DeLano Scientific LLC, 2007, from http://www.pymol.org